Yinhu Qingwen Granule in the Treatment of Viral Pneumonia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-12-31

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a non-randomized single arm clinical study to observe the effect of Yinhu Qingwen Granule in the relief of fever and improvement of related-symptoms of patients with viral pneumonia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Assess the Safety, Tolerability and Preliminary Efficacy of HH-120 for the Treatment of COVID-19

NCT06039163

COVID-19

COMPLETED PHASE1

Qinqiao Yan Shu Granules for the Treatment of Acute Pharyngitis (Exterior Wind-Heat Syndrome) Phase II Clinical Trial

NCT06932328

Acute Pharyngitis

RECRUITING PHASE2

Clinical Trial of Jinzhen Oral Liquid in Treating Children With COVID-19 Infection

NCT05507489

COVID-19 Child, Only

UNKNOWN NA

A Study to Learn About The Study Medicine (Called PF-06823859) in Healthy Chinese Participants

NCT05257798

Healthy

COMPLETED PHASE1

MG Granules Improve COVID-19 Efficacy and Safety of Convalescent Exercise Tolerance

NCT05722093

COVID-19

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Preliminary pharmacodynamic and toxicological studies can show that Yinhu Qingwen Granule has a certain effect on pneumonia caused by various viruses, and its safety is good. This study aims to observe the effect of Yinhu Qingwen Granule in the relief of fever and improvement of related-symptoms of patients with viral pneumonia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Viral Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Yinhu Qingwen Granule

For mild and common patients, take 1 bag 2 times a day. For severe patients, take 1 bag 3 times a day. All treatment should be used for 10 days unless all the symtopms of patient with the viral pneumonia are relieved.

Group Type EXPERIMENTAL

Yinhu Qingwen Granules

Intervention Type DRUG

For mild and common patients, take 1 bag 2 times a day. For severe patients, take 1 bag 3 times a day.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Yinhu Qingwen Granules

For mild and common patients, take 1 bag 2 times a day. For severe patients, take 1 bag 3 times a day.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of viral pneumonia;
* Clinical diagnosis of Shi-du-yun-jie Zheng (damp stagnation syndrome) according to Chinese medicine, including fever,cough,sore throat,stuffy chest,irritability and thirst,short yellow urine,constipation or loose stool,thick and greasy yellow coating,and slippery pulse;
* Chest CT showed signs of acute exudative pneumonia in the lungs;
* Over 18 years old, regardless of gender, voluntarily signed an informed consent form;
* Those who were hospitalized and were accompanied by fever (body temperature ≥37.3℃) and respiratory tract symptoms like cough or dyspnea, when they were enrolled.

Exclusion Criteria

* Patients that are susceptible to sensitivity or known to be allergic to the study drug;
* Patients whose white blood cell count ≥12×10\^9 or neutrophil percentage ≥80%;
* Patients whose weight is less than 40 kg;
* Patients with respiratory failure or need mechanical ventilation;
* Patients with shock;
* Patients required to be in ICU monitoring and treatment;
* Patients participated in other clinical trials within 1 month;
* Patients with known renal impairment;
* Patients with any of the following laboratory parameter abnormalities during the screening period or within 24 hours before screening: ALT or AST level\> 5 times the upper limit of normal range (ULN) or-ALT or AST level \> 3 times ULN and total bilirubin level\> 2 times ULN;
* Patients with immune system diseases and long-term use of immunosuppressive agents;
* Pregnant or breastfeeding women, or who have a positive pregnancy test during the screening period, or plan to become pregnant within 3 months after the study treatment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No